BRPI0916624A2 - anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico - Google Patents

anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico

Info

Publication number: BRPI0916624A2
Authority: BR; Brazil
Prior art keywords: hepcidin; quantifying; kit; selective; protein
Prior art date: 2008-08-06

Application number

BRPI0916624A

Other languages

English (en)

Inventor

Derrick Ryan Witcher

Donmienne Doen Mun Leung

Peng Luan

Pia Pauliina Yachi

Ying Tang

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-06

Filing date

2009-07-29

Publication date

2015-12-01

2009-07-29 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2015-12-01 Publication of BRPI0916624A2 publication Critical patent/BRPI0916624A2/pt

Links

XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 title 2
102400001151 Hepcidin-25 Human genes 0.000 title 2
101800003310 Hepcidin-25 Proteins 0.000 title 2
239000013060 biological fluid Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
General Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BRPI0916624A 2008-08-06 2009-07-29 anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico BRPI0916624A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US8655708P	2008-08-06	2008-08-06
PCT/US2009/052044 WO2010017070A1 (en)	2008-08-06	2009-07-29	Anti-hepcidin-25 selective antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
BRPI0916624A2 true BRPI0916624A2 (pt)	2015-12-01

Family

ID=41165490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0916624A BRPI0916624A2 (pt)	2008-08-06	2009-07-29	anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico

Country Status (19)

Country	Link
US (1)	US8609817B2 (pt)
EP (1)	EP2328931B1 (pt)
JP (1)	JP5730200B2 (pt)
KR (1)	KR101462307B1 (pt)
CN (1)	CN102112489B (pt)
AU (1)	AU2009279865B2 (pt)
BR (1)	BRPI0916624A2 (pt)
CA (1)	CA2733497C (pt)
DK (1)	DK2328931T3 (pt)
EA (1)	EA201170312A1 (pt)
ES (1)	ES2432018T3 (pt)
IL (1)	IL210643A (pt)
MX (1)	MX2011001363A (pt)
NZ (1)	NZ590863A (pt)
PL (1)	PL2328931T3 (pt)
PT (1)	PT2328931E (pt)
UA (1)	UA103032C2 (pt)
WO (1)	WO2010017070A1 (pt)
ZA (1)	ZA201100261B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2543630T3 (es) *	2003-04-01	2015-08-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y sus epítopos
TWI409276B (zh) *	2007-11-02	2013-09-21	Lilly Co Eli	抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
EP3299386A1 (en)	2010-08-16	2018-03-28	Pieris Pharmaceuticals GmbH	Binding proteins for hepcidin
JP6305345B2 (ja)	2011-12-12	2018-04-04	ピエリスファーマシューティカルズゲーエムベーハー	鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法
US10316103B1 (en)	2012-03-30	2019-06-11	Biocare Medical, Llc	Systems and methods for anti-Uroplakin III antibodies
US20140120560A1 (en) *	2012-10-26	2014-05-01	Claresa Levetan	Generation of new pancreatic beta cells
WO2014100220A2 (en)	2012-12-18	2014-06-26	Biocare Medical, Llc	Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
ES2695166T3 (es) *	2013-03-15	2019-01-02	Intrinsic Lifesciences Llc	Anticuerpos antihepcidina y usos de los mismos
JP6506267B2 (ja) *	2013-10-03	2019-04-24	バイオケアメディカル，エルエルシー	抗ｓｏｘ１０抗体のシステムおよび方法
JPWO2016027469A1 (ja) *	2014-08-21	2017-06-01	国立大学法人旭川医科大学	ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法
WO2016049036A1 (en) *	2014-09-22	2016-03-31	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
EP3268027B1 (en)	2015-03-13	2022-11-02	Institut National de la Santé et de la Recherche Médicale (INSERM)	Hepcidin antagonists for use in the treatment of inflammation
CA3038894A1 (en)	2016-09-28	2018-04-05	Board Of Regents, The University Of Texas System	Antibody and protein therapeutic formulations and uses thereof
BR112019013107A2 (pt)	2016-12-22	2019-12-17	Univ Degli Studi Magna Graecia Catanzaro	anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos
WO2018234538A1 (en)	2017-06-23	2018-12-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM
CN109948371B (zh) *	2019-03-07	2021-06-25	深圳市智税链科技有限公司	为区块链节点发放身份证书的方法及相关装置
WO2022154121A1 (ja) *	2021-01-18	2022-07-21	富士フイルム和光純薬株式会社	ヘプシジンの吸着抑制剤、吸着抑制方法、標準品、試薬、キットおよび測定方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000073454A1 (en)	1999-06-02	2000-12-07	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en)	1999-08-30	2001-07-17	Incyte Genomics, Inc.	Polycyclic aromatic hydrocarbon induced molecules
EP2186524B1 (en)	2001-05-25	2018-02-21	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
CN1173737C (zh)	2002-10-21	2004-11-03	钱忠明	Hepcidin(海魄喜定)在制药中的应用
US8017737B2 (en)	2002-11-19	2011-09-13	Hasan Kulaksiz	Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
JP4638350B2 (ja)	2002-11-19	2011-02-23	ディーアールジー・インターナショナル，インコーポレイテッド	ヒトまたは動物の組織、血液もしくは体液中のヘプシジンの存在または量を検出する方法
US7411048B2 (en)	2002-11-19	2008-08-12	Drg International, Inc.	Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US20050033029A1 (en)	2003-06-30	2005-02-10	Jin Lu	Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005033327A2 (en)	2003-09-29	2005-04-14	Biosite Incorporated	Methods and compositions for the diagnosis of sepsis
AU2003271174A1 (en) *	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
US7723063B2 (en)	2004-04-28	2010-05-25	Intrinsic Lifesciences	Methods for measuring levels of bioactive human hepcidin
EP1869462B1 (en)	2005-03-11	2013-05-08	Ciphergen Biosystems, Inc.	Biomarkers for ovarian cancer and endometrial cancer: hepcidin
TW201307390A (zh)	2007-02-02	2013-02-16	Amgen Inc	海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
GR1006896B (el)	2007-08-24	2010-07-20	Ελληνικο Ινστιτουτο Παστερ,	Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
ATE553778T1 (de) *	2007-10-02	2012-05-15	Inst Nat Sante Rech Med	Für humanes hepcidin spezifische antikörper
TWI409276B (zh)	2007-11-02	2013-09-21	Lilly Co Eli	抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
EP2294087B1 (en)	2008-05-01	2014-05-14	Amgen, Inc.	Anti-hepcidin antibodies and methods of use

2009
- 2009-07-29 NZ NZ590863A patent/NZ590863A/xx not_active IP Right Cessation
- 2009-07-29 DK DK09790908.9T patent/DK2328931T3/da active
- 2009-07-29 PL PL09790908T patent/PL2328931T3/pl unknown
- 2009-07-29 PT PT97909089T patent/PT2328931E/pt unknown
- 2009-07-29 US US13/055,201 patent/US8609817B2/en not_active Expired - Fee Related
- 2009-07-29 ES ES09790908T patent/ES2432018T3/es active Active
- 2009-07-29 KR KR1020117002748A patent/KR101462307B1/ko not_active Expired - Fee Related
- 2009-07-29 WO PCT/US2009/052044 patent/WO2010017070A1/en active Application Filing
- 2009-07-29 BR BRPI0916624A patent/BRPI0916624A2/pt not_active IP Right Cessation
- 2009-07-29 CA CA2733497A patent/CA2733497C/en active Active
- 2009-07-29 AU AU2009279865A patent/AU2009279865B2/en not_active Ceased
- 2009-07-29 MX MX2011001363A patent/MX2011001363A/es active IP Right Grant
- 2009-07-29 UA UAA201101111A patent/UA103032C2/uk unknown
- 2009-07-29 EP EP09790908.9A patent/EP2328931B1/en active Active
- 2009-07-29 CN CN200980129864.0A patent/CN102112489B/zh not_active Expired - Fee Related
- 2009-07-29 JP JP2011522119A patent/JP5730200B2/ja not_active Expired - Fee Related
- 2009-07-29 EA EA201170312A patent/EA201170312A1/ru unknown
2011
- 2011-01-10 ZA ZA2011/00261A patent/ZA201100261B/en unknown
- 2011-01-13 IL IL210643A patent/IL210643A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK2328931T3 (da)	2013-09-30
EA201170312A1 (ru)	2012-03-30
JP5730200B2 (ja)	2015-06-03
KR20110031963A (ko)	2011-03-29
CA2733497C (en)	2015-06-02
HK1156326A1 (en)	2012-06-08
US20110189190A1 (en)	2011-08-04
KR101462307B1 (ko)	2014-11-17
AU2009279865B2 (en)	2013-10-10
NZ590863A (en)	2012-10-26
US8609817B2 (en)	2013-12-17
ES2432018T3 (es)	2013-11-29
EP2328931A1 (en)	2011-06-08
ZA201100261B (en)	2012-06-27
WO2010017070A1 (en)	2010-02-11
CN102112489A (zh)	2011-06-29
UA103032C2 (uk)	2013-09-10
EP2328931B1 (en)	2013-08-14
IL210643A0 (en)	2011-03-31
JP2011530514A (ja)	2011-12-22
CN102112489B (zh)	2014-05-14
PT2328931E (pt)	2013-11-07
MX2011001363A (es)	2011-04-26
PL2328931T3 (pl)	2014-01-31
AU2009279865A1 (en)	2010-02-11
CA2733497A1 (en)	2010-02-11
IL210643A (en)	2015-09-24

Publication	Publication Date	Title
BRPI0916624A2 (pt)	2015-12-01	anticorpos monoclonais seletivos anti-hepcidina-25, seus usos, bem como método e kit para quantificar a quantidade de proteína hepcidina-25 em uma amostra de tecido ou fluido biológico
BRPI0716163A2 (pt)	2013-09-17	mÉtodos e kits para detectar fluido cÉrebro-espinhal em uma amostra
BR112012013362A2 (pt)	2016-03-01	sistema para a determinação de um valor para pelo menos um parâmetro que descreve a atividade microbiana de organismos biológicos individuais em uma amostra de líquido, e, método para a determinação da atividade microbiana em uma amostra de líquido
BRPI0813985A2 (pt)	2017-08-01	anticorpos humanos para cd20 humana e método para seu uso.
BRPI0821148A2 (pt)	2015-06-16	Dispositivo e método para análise microbiológica de amostras biológicas
WO2008021290A3 (en)	2008-11-13	Organ-specific proteins and methods of their use
BRPI0807532A2 (pt)	2014-06-10	Fluido tensoativo viscoelástico multicomponente e método de utilização como um fluido de fraturamento
BR112012009846B8 (pt)	2021-05-25	método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
BRPI1011760A2 (pt)	2015-10-06	método para prevenir ou reduzir coagulação no trato gastrointestinal superior de um indivíduo, e, uso de proteína anticoagulante.
BRPI0717633A2 (pt)	2014-02-18	Anticorpo, composição farmacêutica, e, métodos para detectar uma célula expressando cxcr7 em uma amostra biológica, para tratar, prevenir ou melhorar uma doença e para identificar um modulador de cxcr7
IT1406051B1 (it)	2014-02-06	Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
EP2116837A4 (en)	2014-05-14	INSTRUMENT FOR MEASURING THE CONCENTRATION OF PARTICLES IN A LIQUID, MEASURING METHOD AND MEASUREMENT PROGRAM
BRPI0722092A2 (pt)	2014-04-01	Proteínas de plantas antifúngicas e métodos para seu uso
BRPI0916101A2 (pt)	2016-09-27	"método para determinar o estágio de uma gravidez, dispositivo adaptado para detectar os níveis/a quantidade de hpl ou de um fragmento do mesmo em uma amostra de fluido corpóreo derivado de uma fêmea humana, kit e uso de um anticorpo anti-hpl"
EP2319937A4 (en)	2011-08-17	METHOD FOR MEASURING BLOOD COMPONENTS ON THE BASIS OF HEMOLYSED WHOLE BLOOD AND KIT FOR THE PROCESS
BRPI0920695A2 (pt)	2016-01-12	detecção de ácido nucleico npm1 em fluidos corpóreos acelulares
BR112013002041A2 (pt)	2016-05-31	composição de reagente multiuso e método para determinar simultaneamente as concentrações de pelo menos dois analitos em uma amostra de água
BRPI0921140A8 (pt)	2017-10-24	sistema e método de diagnóstico de doenças em bovinos usando análise de auscuta
BRPI0814631A2 (pt)	2015-07-14	Adesivo, método para aderir tecido biológico, kit, e artigo.
EP2732288A4 (en)	2014-05-21	BIOLOGICAL MICROCHIP TO ESTIMATE THE CONCENTRATION OF IMMUNOGLOBULIN E AND G IN HUMAN BLOOD, TEST METHOD AND REAGENT SET THEREFOR
PT2294176T (pt)	2018-05-25	Adaptador de câmara de amostra, em particular para a criopreservação de amostras biológicas
BRPI1015458A2 (pt)	2016-04-19	método para detectar anticorpo contra sith-1 em amostra biológica
BRPI1009460A2 (pt)	2016-03-01	domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra.
SI2279264T1 (sl)	2015-11-30	Postopek za karakteriziranje biološke aktivnosti jajčec Trichurisa
BR112012009023A2 (pt)	2019-09-24	método pra detecção. diferenciação e identificação de eubactérias específica de táxons em uma amostra biológica por meio de técnicas de análise de sequenciamento e kit

Legal Events

Date	Code	Title	Description
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.